Chicago’s AbbVie (NYSE: ABBV) has inked a deal with Voyager Therapeutics (Nasdaq: VYGR), sending shares in the gene therapy company up almost a quarter in trading on Friday.
Voyager, which is focused on developing therapies for severe neurological diseases, agreed terms for a global strategic collaboration and option agreement for certain antibody candidates to treat Parkinson's disease.
The firms will also explore the potential for the vectorized antibodies to treat other diseases which are characterized by a similar pathology.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze